Clinical trials
Advanced Malignancies clinical trials
Below are recruiting advanced malignancies clinical trials, each written for real people, not researchers. We’re tracking 334 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07192107RecruitingPhase 1/Phase 2
Study of MHB042C for advanced solid tumors
This trial tests a new drug called MHB042C for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective.
Guangzhou, GuangdongAges 18 years+ - NCT05099809Recruiting
Hyperthermia plus treatment for locally advanced cancers
This registry study looks at whether adding hyperthermia (raising body temperature) is safe and effective for people with certain locally advanced, non-spread cancers. It will follow outcomes to help doctors understand who may benefit and what side effects to expect.
Sevāgrām, MaharashtraAges 18 years+ - NCT07280832RecruitingPhase 1/Phase 2
Study of JMT108 for advanced melanoma
This trial tests a new drug, JMT108, for people with advanced melanoma that can't be removed by surgery or has spread. It's for those who have tried other treatments or have no good options left.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05315167RecruitingPhase 1/Phase 2
Study drug PRJ1-3024 for advanced solid tumors
This trial tests how safe PRJ1-3024 is and how the body handles it, and it also looks for early signs that it can shrink advanced solid tumors. It may help people whose cancer can’t be treated with standard options.
Zhengzhou, HenanAges 18 years+ - NCT07189195RecruitingPhase 1
TR-002 for advanced solid tumors and pancreatic cancer
This trial tests a new drug called TR-002 in people with advanced solid tumors (cancer that has spread) who have run out of standard treatment options. It includes a specific group for people with pancreatic cancer that is no longer responding to chemotherapy.
Sacramento, CaliforniaAges 18 years+ - NCT06364410RecruitingPhase 1
Testing a new drug combo for stomach and other solid tumors
This trial tests a combination of two drugs, trastuzumab deruxtecan and azenosertib, for people with stomach cancer or other solid tumors that have a specific protein called HER2. It aims to see if this combination can help when other treatments have stopped working.
Houston, TexasAges 18 years+ - NCT06311214RecruitingPhase 2
Personalized ADC therapy for advanced solid tumors
This trial tests personalized antibody-drug conjugates (ADCs) for advanced solid tumors. It looks for specific proteins on your tumor cells to match you with a treatment that targets them directly.
Duarte, CaliforniaAges 18 years+ - NCT06597539Recruiting
PET scan to monitor immunotherapy in advanced liver cancer
This trial uses a special PET scan (68Ga-grazytracer) to see how well immunotherapy is working in people with advanced liver or bile duct cancer. The goal is to find a better way to monitor treatment response.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06470971RecruitingPhase 2
Siltuximab to prevent severe side effects during immunotherapy rechallenge
This trial tests if siltuximab can prevent severe immune-related side effects when patients restart immunotherapy (anti-PD-1/PD-L1) after previous severe side effects. It aims to make rechallenge safer for people with advanced cancer.
Columbus, OhioAges 18 years+ - NCT06026605RecruitingEarly Phase 1
Study of WTX212A for advanced solid tumors
This trial tests a new drug called WTX212A for people with advanced solid tumors that are no longer responding to standard treatments. The goal is to find the best dose and see if the drug is safe and effective.
Hangzhou, ZhejiangAges 18–75 - NCT04749108RecruitingPhase 2/Phase 3
Tailored treatment for locally advanced rectal cancer after FOLFIRINOX
This trial studies a more customized treatment plan for people with locally advanced rectal (bowel) cancer after they receive FOLFIRINOX chemotherapy. It aims to reduce tumor spread risk and improve outcomes by tailoring the next steps based on scan details and your health status.
Marseille, Bouches Du RhôneAges 18 years+ - NCT05865002RecruitingPhase 1
Safety and drug test for AUR107 in advanced cancers
This early-phase study tests whether AUR107 is safe and may help shrink or control advanced solid tumors that have come back or progressed. You may be considered if standard treatments no longer work and you meet specific blood, organ, and health requirements.
Vijayawada, Andhra PradeshAges 18 years+ - NCT06484816RecruitingPhase 1
TGRX-1942 study for advanced solid tumor or blood cancer
This trial tests an experimental drug (TGRX-1942) for people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goal is to find a safe dose and see how well the drug works.
Hangzhou, ZhejiangAges 18 years+ - NCT07752953Recruiting
Personalized immune cell therapy for solid tumors
This trial tests a personalized cancer vaccine made from your own immune cells to help your body fight the tumor. It is for people with solid tumors that have not responded to other treatments.
Qinhuangdao, HebeiAges 18–75 - NCT05205850RecruitingPhase 1/Phase 2
RC118 for solid cancers with Claudin 18.2 on tumor cells
This Phase 1/2 study tests RC118, a cancer medicine, in people with advanced or spread solid tumors that cannot be removed by surgery. It focuses on tumors that show a specific marker called Claudin 18.2, which may help the treatment work better for some patients.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07073534RecruitingPhase 1/Phase 2
A study of two drugs for advanced solid tumors
This trial tests two drugs combined—SHR-1501 and adbelizumab—for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT07444268RecruitingPhase 1
Study of how DSP-5336 is processed in the body in advanced blood cancer patients
This trial looks at how your body absorbs, breaks down, and gets rid of the study drug DSP-5336 after a single dose. It is for people with advanced blood cancers that have come back or not responded to other treatments.
Chapel Hill, North CarolinaAges 18 years+ - NCT06994806RecruitingPhase 1
KQB168 for advanced solid tumors post immunotherapy
This trial tests a new oral drug (KQB168) given alone or with other medicines for people with advanced solid tumors that have not responded to immunotherapy. The goal is to see if it is safe and can help shrink or slow the growth of cancer.
Phoenix, ArizonaAges 18 years+ - NCT07207707RecruitingPhase 1
KQB548 for advanced solid tumors with KRAS G12D mutation
This trial tests a new drug called KQB548 for people with certain advanced cancers (pancreatic, colorectal, or lung) that have a specific genetic change called KRAS G12D. It's for those whose cancer has continued to grow despite previous treatments.
La Jolla, CaliforniaAges 18 years+ - NCT06759649RecruitingPhase 1
Study of COM503 for advanced solid tumors
This trial tests a new drug called COM503 for people with advanced solid tumors that have not responded to or cannot be treated with standard therapies. It aims to see if the drug is safe and how well it works.
New Haven, ConnecticutAges 18 years+ - NCT06958679RecruitingPhase 1
Study of SYS6005 for advanced solid tumors and lymphomas
This study tests a new drug (SYS6005) that targets a protein called ROR1 on certain cancer cells. It is for people with advanced solid tumors or B-cell lymphomas that have stopped responding to other treatments.
TianjinAges 18 years+ - NCT06878612RecruitingPhase 1
Personalized tumor cell vaccine for advanced solid tumors
This trial tests a new vaccine made from your own tumor cells to see if it can help your immune system fight the cancer. It is for people with advanced solid tumors that have not responded to other treatments.
Chengdu, SichuanAges 18–65 - NCT05707325RecruitingEarly Phase 1
Testing a lab-made red blood cell treatment for advanced cancers
This early trial studies whether an engineered (lab-made) red blood cell treatment is safe and tolerable, and whether it may show early anti-cancer activity. It may help people with advanced cancers whose disease has not responded well to standard options.
Hangzhou, ZhejiangAges 18–75 - NCT05880043RecruitingPhase 1/Phase 2
IV NK cell treatment for advanced cancers that returned
This Phase 1/2 study tests an intravenous (IV) immune-cell therapy made from donors (allogeneic NK cells) to treat advanced solid tumors, relapsed/refractory non-Hodgkin lymphoma, or multiple myeloma. It may help by targeting cancer cells more directly, but early-phase trials mainly focus on safety and finding the right dosing.
SeoulAges 19 years+
Hear when a new Advanced Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced malignancies?
- Yes. Clin2 currently lists 334 recruiting advanced malignancies studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced malignancies trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced malignancies trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.